By Katherine Hamilton
Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025.
The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months.
The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year.
Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet.
Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:08 ET (13:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。